Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Exponent expects Q4 2024 Revenues before reimbursements to grow in the mid-single digits and EBITDA to be 23.5% to 24.5% of revenues before reimbursements.

Author: Benzinga Newsdesk | October 24, 2024 03:43pm

Exponent (NASDAQ:EXPO) .

Posted In: EXPO